Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mylan Inc announces CE mark for myt4 point-of-care cd4 diagnostic test


Thursday, 9 Jan 2014 07:30am EST 

Mylan Inc:Says Zyomyx's MyT4 point-of-care CD4 diagnostic test has received the CE Certificate of conformity in the European Union.Says the MyT4 CD4 test can now bear the CE Mark, which demonstrates that the MyT4 CD4 test complies with stringent requirements related to the quality, safety, and performance of in vitro medical devices found in the applicable EU laws.Says Mylan and Zyomyx, the manufacturer of MyT4, announced in July 2013 their exclusive distribution agreement for the test in developing countries. 

Company Quote

57.6
0.63 +1.11%
26 Dec 2014